Sun Pharma to test pancreatitis drug in Covid-19 patients in India


Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in Covid-19 patients.

The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for Covid-19, which currently has no approved treatment or vaccine. Sun Pharma said here the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for Covid-19 patients.....

This article is no longer available in our repository.

There could be multiple reasons for this.